Acute kidney injury and bisphosphonate use in cancer: A report from the research on adverse drug events and reports (RADAR) project

Journal of Oncology Practice

Volumn 9, Issue 2, 2013, Pages 101-106

  Edwards, Beatrice J ^a   Usmani, Sarah ^a   Raisch, Dennis W ^a   McKoy, June M ^a   Samaras, Athena T ^a   Belknap, Steven M ^a   Trifilio, Steven M ^a   Hahr, Allison ^a   Bunta, Andrew D ^a   Abu Alfa, Ali ^a   Langman, Craig B ^a   Rosen, Steve T ^a   West, Dennis P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CREATININE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ARTICLE; BREAST CANCER; CANCER PATIENT; CREATININE BLOOD LEVEL; DEATH; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW;

ACUTE KIDNEY INJURY; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 84882778870     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000486     Document Type: Article

References (70)

1. Green JR: Bisphosphonates: Preclinical review. Oncologist 9:3-13, 2004 (suppl 4)
2. Gasser AB, Morgan DB, Fleisch HA, et al: The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 43:31-45, 1972
3. Di Salvatore M, Orlandi A, Bagalà C, et al: Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 44:139-146, 2011
4. Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176, 2001
5. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998 (Pubitemid 28045531)
6. Tsakiris DJ, Stel VS, Finne P, et al: Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: An ERA-EDTA Registry study. Nephrol Dial Transplant 25:1200-1206, 2010
7. Kyle RA, Rajkumar SV: Treatment of multiple myeloma: A comprehensive review. Clin Lymphoma Myeloma 9:278-288, 2009
8. Corso A, Ferretti E, Lazzarino M: Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology 10:215-224, 2005 (Pubitemid 41801138)
9. Croucher PI, De Hendrik R, Perry MJ, et al: Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18:482-492, 2003 (Pubitemid 36241065)
10. Guenther A, Gordon S, Tiemann M, et al: The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 126:239-246, 2010
11. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
12. Pavlakis N, Stockler M: Bisphosphonates for breast cancer. Cochrane Database Syst Rev, CD003474, 2002
13. Perazella MA, Markowitz GS: Bisphosphonate nephrotoxicity. Kidney Int 74:1385-1393, 2008
14. Bennett CL, Nebeker JR, Lyons EA, et al: The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 293:2131-2140, 2005 (Pubitemid 40617066)
15. Evans SJ, Waller PC, Davis S: Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483-486, 2001 (Pubitemid 34100774)
16. Hauben M, Zhou X: Quantitative methods in pharmacovigilance: Focus on signal detection. Drug Saf 26:159-186, 2003 (Pubitemid 36308102)
17. DuMouchel W, Smith ET, Beasley R, et al: Association of asthma therapy and Churg-Strauss syndrome: An analysis of postmarketing surveillance data. Clin Ther 26:1092-1104, 2004 (Pubitemid 39141812)
18. Body JJ, Pfister T, Bauss F: Preclinical perspectives on bisphosphonate renal safety. Oncologist 10:3-7, 2005 (suppl 1)
19. Munier A, Gras V, Andrejak M, et al: Zoledronic acid and renal toxicity: Data from French adverse effect reporting database. Ann Pharmacother 39:1194-1197, 2005 (Pubitemid 40943168)
20. Stylianou K, Lioudaki E, Papadimitraki E, et al: Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Nephrol Dial Transplant 26:1742-1745, 2011
21. Zazgornik J, Grafinger P, Biesenbach G, et al: Acute renal failure and alendronate. Nephrol Dial Transplant 12:2797-2798, 1997
22. Markowitz GS, Appel GB, Fine PL, et al: Collapsing focal segmental glomerulosclerosis following treatment with high dose pamidronate. J Am Soc Nephrol 12:1164-1172, 2001 (Pubitemid 32472629)
23. Markowitz GS, Fine PL, Stack JI, et al: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281-289, 2003 (Pubitemid 36714182)
24. Yoshizawa H, Akimoto T, Nishino K, et al: Nephrotic syndrome and renal failure in a patient with metastatic breast cancer. Clin Exp Nephrol 15:567-571, 2011
25. Jaffe JA, Kimmel PL: Chronic nephropathies of cocaine and heroin abuse: A critical review. Clin J Am Soc Nephrol 1:655-667, 2006
26. Korbet SM: Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 9:1333-1340, 1998
27. Barri YM, Munshi NC, Sukumalchantra S, et al: Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65:634-641, 2004 (Pubitemid 38130659)
28. Sauter M, Jülg B, Porubsky S, et al: Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: Mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 47:1075-1080, 2006 (Pubitemid 43767326)
29. US Food and Drug Administration: Postmarket Reviews - Volume 2, Number 2, 2009. Zoledronic acid renal impairment and acute renal failure. 2009
30. Novartis Pharmaceutical Corporation: Safety Alert: Zometa, Dear Doctor Letter, FDA 2005
31. US Food and Drug Administration: Reclast (zoledronic acid): Drug safety communication - New contraindication and updated warning on kidney impairment, 2011
32. European Medicine Agency: European Medicines Agency concludes class review of bisphosphonates and atypical fractures, 2011
33. Australian Government: Australian Public Assessment Report for Zoledronic Acid. August 2011. http://www.tga.gov.au/pdf/auspar/auspar-aclasta.pdf
34. Australian Government TGA: Australian Adverse Drug Reactions Bulletin, Vol 26, No 5, 2007
35. Health C: Updated renal safety information on Zometa (zoledronic acid) and Aclasta (zoledronic acid) - Novartis Pharmaceuticals Canada, 2009
36. Plosker GL, Goa KL: Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47:945-982, 1994 (Pubitemid 24170834)
37. Adami S, Zamberlan N: Adverse effects of bisphosphonates. A comparative review. Drug Saf 14:158-170, 1996
38. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001 (Pubitemid 33759002)
39. Tralongo P, Repetto L, Di Mari A, et al: Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 67:112-116, 2004 (Pubitemid 39482678)
40. Ali SM, Esteva FJ, Hortobagyi G, et al: Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19:3434-3437, 2001 (Pubitemid 32642197)
41. Cal JC, Daley-Yates PT: Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice. Toxicology 65:179-197, 1990
42. Lin JH, Duggan DE, Chen IW, et al: Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19:926-932, 1991
43. Lin JH, Chen IW, Deluna FA, et al: Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos 20:608-613, 1992
44. Ullrich KJ, Rumrich G, Burke TR, et al: Interaction of alkyl/arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule. J Pharmacol Exp Ther 283:1223-1229, 1997 (Pubitemid 28016497)
45. Diel IJ, Bergner R, Grötz KA: Adverse effects of bisphosphonates: Current issues. J Support Oncol 5:475-482, 2007
46. Montseny JJ, Kleinknecht D, Meyrier A, et al: Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transpl 13:1438-1445, 1998 (Pubitemid 28254318)
47. Van Poznak CH, Von Roenn JH, Temin S: American Society of Clinical Oncology clinical practice guideline update: Recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract 7:117-121, 2011
48. Hortobagyi GN, Theriault RL, Lipton A, et al: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038-2044, 1998 (Pubitemid 28265038)
49. Hultborn R, Gundersen S, Ryden S, et al: Efficacy of pamidronate in breast cancer with bone metastases: A randomized double-blind placebo controlled multicenter study. Acta Oncol 35:73-4, 1996 (suppl 5)
50. Lipton A, Theriault RL, Hortobagyi GN, et al: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082-1090, 2000 (Pubitemid 30127670)
51. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003 (Pubitemid 46606220)
52. Berenson JR, Hillner BE, Kyle RA, et al: American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719-3736, 2002 (Pubitemid 34983232)
53. Kyle RA, Yee GC, Somerfield MR, et al: American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464-2472, 2007 (Pubitemid 46999218)
54. Porter GA, Palmer BF, Henrich WL: Clinical relevance, in DeBroe ME, Porter GA (eds): Clinical Nephrotoxins: Renal Injury From Drugs and Chemicals. Dordrecht, the Netherlands, Kluwer Academic Publishers, pp 3-20, 2003
55. Henrich WL: Nephrotoxicity of several newer agents. Kidney Int 67:S107-S109, 2005
56. Fauci AS (ed): Harrisons Online (17th ed). Columbus, OH, McGraw Hill, 2008
57. Bellomo R, Ronco C, Kellum JA, et al: Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204-R212, 2004
58. Ostermann M, Chang R, Riyadh ICU Program Users Group: Correlation between the AKI classification and outcome. Crit Care 12:R144, 2008
59. Mehta RL, Kellum JA, Shah SV, et al: Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31, 2007
60. Lasser KE, Allen PD, Woolhandler SJ, et al: Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220, 2002 (Pubitemid 34441937)
61. Fontanarosa PB, Rennie D, DeAngelis CD: Postmarketing surveillance-lack of vigilance, lack of trust. JAMA 292:2647-2650, 2004 (Pubitemid 39577521)
62. Drazen JM: COX-2 inhibitors-a lesson in unexpected problems. N Engl J Med 352:1131-1132, 2005
63. Brewer T, Colditz GA: Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs. JAMA 281:824-829, 1999 (Pubitemid 29113743)
64. Ladewski LA, Belknap SM, Nebeker JR, et al: Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: First results from the research on adverse drug events and reports project. J Clin Oncol 21:3859-3866, 2003 (Pubitemid 46606242)
65. Piazza-Hepp TD, Kennedy DL: Reporting of adverse events to MedWatch. Am J Health Syst Pharm 52:1436-1439, 1995
66. Moore TJ, Psaty BM, Furberg CD: Time to act on drug safety. JAMA 279:1571-1573, 1998 (Pubitemid 28233014)
67. Wood AJ, Stein CM, Woosley R: Making medicines safer-the need for an independent drug safety board. N Engl J Med 339:1851-1854, 1998 (Pubitemid 29005794)
68. Belknap SM, Georgopoulos CH, West DP, et al: Quality of methods for assessing and reporting serious adverse events in clinical trials of cancer drugs. Clin Pharmacol Ther 88:231-236, 2010
69. Dorr DA, Burdon R, West DP, et al: Quality of reporting of serious adverse drug events to an institutional review board: A case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res 15:3850-3855, 2009
70. Bellomo R, Kellum JA, Mehta R, et al: Acute Dialysis Quality Initiative II: The Vicenza conference. Curr Opin Crit Care 8:505-508, 2002 (Pubitemid 35388203)